Ações da Gland Pharma atingem máxima de 52 semanas após resultados

20 de maio de 2026

Reportado por IA

As ações da Gland Pharma alcançaram uma nova máxima de 52 semanas após a empresa reportar resultados sólidos referentes ao trimestre de março e ao ano fiscal. A unidade europeia Cenexi mostrou sinais de recuperação, enquanto lançamentos de novos produtos e ampliações de capacidade reforçaram as perspectivas.

Os papéis da Gland Pharma subiram para o seu nível mais alto em um ano após a divulgação de números trimestrais e anuais robustos. A empresa destacou a melhoria da rentabilidade em sua subsidiária europeia Cenexi como um fator positivo fundamental.

Artigos relacionados

Laurus Labs stock rises 30 percent on FY26 results

Laurus Labs reported strong financial results for fiscal 2026, driving a 30 percent gain in its share price. Growth in contract manufacturing and a better product mix supported the performance.

Sun Pharma reports strong quarterly growth but eyes margin pressure

24 de maio de 2026 Reportado por IA

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Europe

Profits rise at DAX companies despite falling revenues

Business

Retail investors gain from small-cap stock rallies

Africa

JSE companies report strong earnings growth in latest updates

European equities suffer steep weekly losses amid Middle East tensions

European stocks closed the week lower on Friday, with the STOXX 600 index hitting a two-week low. Investors cited concerns over growth and inflation from the ongoing Middle East conflict disrupting energy supplies. While technology shares gained, healthcare and financial sectors declined.

Nine BSE smallcap stocks surged up to 170% with strong Q4 profits

01 de maio de 2026 Reportado por IA

Nine BSE smallcap companies delivered standout performances in the March 2026 quarter, with net profits surging over 50% year-on-year and share prices rising 50% to 170% in the past year. Four of these stocks became multibaggers, more than doubling investor returns. Data from ACE Equity highlights the momentum amid mixed results from 168 reporting firms.

Business